Progestosterone therapy for the treatment of non-cancer cachexia: a systematic review

Joanne K Taylor,1 Neil Pendleton2

ABSTRACT

Background Cachexia describes a complex pathological syndrome of muscle wasting, anorexia and weight loss. Progestosterone therapies have been shown to improve appetite and promote weight gain in patients with cachexia; however, research has focused heavily on patients with cancer, and its effectiveness in other diseases remains unclear.

Aims This systematic review aimed to present the evidence available for progestosterone therapy as a treatment for non-cancer cachexia.

Method Surrogate outcome measures used were weight change, lean body mass (LBM), muscle strength, appetite, health-related quality of life (HRQOL) and serum albumin. Both randomised and non-randomised trials were included. A literature search of clinical trials using the medical subject heading (MeSH) terms ‘cachexia’ OR ‘anorexia’ OR ‘weight’ OR ‘frail (truncated)’ OR ‘appetite’ OR ‘wasting syndrome’ PLUS ‘megestrol acetate’ OR ‘medroxyprogesterone acetate’ was performed.

Results Eighteen studies were included in this review; 12 randomised control trials and 6 non-randomised trials. This collated results from 916 patients with HIV/AIDS, end-stage renal failure, chronic obstructive pulmonary disease (COPD) and geriatric cachexia. Meta-analysis comparing progestosterone therapy with placebo concluded mean change in weight was not significant (mean difference (MD) 1.56, 95% CI −0.36 to 3.52, p=0.12). There was little evidence to show significant impact on LBM, and no trials looked at muscle strength. There was a paucity of evidence looking at appetite and HRQOL; however, results were generally positive.

Conclusions Current evidence does not support the use of progestosterone therapies for non-cancer cachexia. There may however be a limited role for its use as an appetite stimulant in a palliative context on a case-by-case basis.

BACKGROUND

Cachexia

Cachexia describes a pathological clinical syndrome characterised by weight loss, anorexia and muscle wasting. It is a clinical description associated with severe, advanced disease and poor prognosis. Cachexia is common in patients with advanced chronic disease with an estimated 25% of patients with chronic obstructive pulmonary disease (COPD) and 25–50% of patients with end-stage renal failure (ESRF) suffering from this syndrome.1,2 Cachexia is a distressing symptom for the patient and family, who fear their loved one ‘wasting away’ or ‘starving to death’.3

The underlying pathogenesis of cachexia remains an area of research; however, there is good evidence to show this is a multifactorial process mediated predominantly by proinflammatory cytokines.4,5 A variety of processes are known to contribute to this syndrome, including anorexia, hypercatabolism, muscle wasting, fatigue, reduced physical exercise, anaemia, raised inflammatory markers and endocrine abnormalities.6,7

Terminology remains variable with syndromes such as ‘anorexia–cachexia syndrome’ and ‘wasting syndrome’ used synonymously. While frequently described in clinical practice, there is a lack of international consensus defining the term ‘cachexia’. In 2008, the Cachexia Consensus Working Group published a proposal for the following definition: ‘Cachexia, is a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle with or without loss of fat mass’.8 Within this publication, a set of diagnosis criteria were proposed. This is shown in box 1 below.
This set of diagnostic criteria can be applied to cachexia secondary to any underlying condition. They have yet to be tested in clinical practice; however, they provide a framework for clinical research. Guidance for the diagnosis of cancer cachexia is more focused on weight loss and sarcopenia, however similarly reference anorexia signs of underlying inflammation.

Treatment of cachexia

Effective strategies to manage cachexia have been slow to evolve. Non-pharmacological strategies such as dietary advice, high-calorie diet and exercise have shown disappointing results. Pharmacological strategies have included progesterone therapy, anabolic steroids, cannabinoids, antidepressants, recombinant growth factor and more recently thalidomide and steroids, cannabinoids, antidepressants, recombinant growth factor and more recently thalidomide and corticosteroids. However, in a Cochrane review originally published in 2005 examining the use of MA for anorexia–cachexia syndrome, this review included all patient groups: patients with cancer, HIV/AIDS and other chronic disease, including cachexia associated with ageing. It concluded that there was sufficient evidence to show MA improves appetite and induces slight weight gain. The 2010 European Palliative Care Research Collaborative (EPCRC) Cachexia Guidelines recommended progesterone therapies ‘should be considered for patients with refractory cachexia and anorexia as a major distressing symptom’ in patients with cancer. Both cited the lack of high-quality research evidence.

It remains unclear if the management of cachexia should be the same regardless of underlying aetiology. There has been an increasing use of MA in patients with cachexia with chronic disease, particularly in a palliative setting. However, the subgroup analyses in the Cochrane review of patients with AIDS or other underlying pathologies were not conclusive. Results were limited in the main part owing to the lack of randomised control trials (RCTs), and important domains such as lean body mass (LBM) were not included, questioning the benefit of any demonstrable weight gain.

This review aims to present an update of the current research looking at efficacy in patients without cancer, including subgroup analysis by underlying aetiology to guide physician’s decision-making in this poorly researched area.

METHODS

This review is based on the methodology laid out in the Cochrane Handbook for Systematic Reviews of Interventions (CHSRI) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. As there were no validated diagnostic criteria for cachexia, surrogate markers were used (based on current working definitions of the cachexia syndrome). A general review of adverse events and safety profile was performed. Meta-analysis of RCTs was performed where enough data were available. Anticipating a lack of data, we have also included a full description and analysis of all the available evidence including randomised and non-randomised trials.

Eligibility criteria

Studies considered for inclusion in this review were RCTs (both blinded and unblinded), non-randomised clinical trials and cross-over trials (both randomised and non-randomised). Studies must have been available in the English language. Trial participants were required to be over the age of 16 and have at least one of the following: clinically suspected cachexia, malnutrition, low body weight/body mass index (BMI), unintentional weight loss and low serum albumin. Patients with a diagnosis of active cancer were excluded. Although ‘geriatric cachexia’ remains a debatable term, it was not felt necessary to exclude these patients form our analysis. Any progesterone therapy administered using the oral route of administration was accepted. Comparison could be made with placebo, alternative doses, preparations and

Box 1

Diagnostic Criteria for Wasting Disease (Cachexia) in Adults

Weight loss of at least 5% in 12 months or less in the presence of underlying illness, PLUS THREE of the following criteria:
- Decreased muscle strength (lowest tertile)
- Fatigue
- Anorexia
- Low fat-free mass index
- Abnormal biochemistry
  - A. Increased inflammatory markers: CRP (>5.0 mg/L), IL-6 (>4.0 pg/mL)
  - B. Anaemia (<12 g/dL)
  - C. Low serum albumin (<3.2 g/dL)

Reprinted from Evans et al, with permission from Elsevier Limited.
concentrations, or other medications/interventions. Trials with a dropout rate of >50% were also excluded.

The measured outcomes of this review can be seen in box 2 below:

**Search methods**

Electronic searches were performed on the following databases: The Cochrane Central Register of Controlled Trials (CENTRAL), Medline, Embase and ClinicalTrials.gov.

**MeSH search terms**

- ‘Trial’ (or selected ‘clinical trials’ in search filter) PLUS
- ‘Cachexia’ OR ‘anorexia’ OR ‘weight’ OR ‘frail (truncated)’ OR ‘appetite’ OR ‘wasting syndrome’ PLUS
- ‘Megestrol acetate’ OR ‘medroxyprogesterone acetate’

A reference check was made of all included studies, and any papers of interest were screened using the criteria as above. Search terms were deliberately kept broad owing to the diverse terminology used for ‘cachexia’. More narrow searches were trialled and important relevant studies were missed.

**Data collection and analysis**

Once all duplicate papers were deleted, abstracts were manually filtered by investigator JKT and irrelevant papers removed. Following this, all remaining papers were reviewed independently by two investigators (JKT and NP). Any studies where parties disagreed were discussed and a moderated decision about inclusion made. Data were managed on Microsoft Excel 2011 and Review Manager (RevMan) software (Collaboration RTC. Review Manager (RevMan). 5.2. Copenhagen, The Nordic Cochrane Centre: The Cochrane Collaboration 2012). Data requests were sent to all authors in cases of missing/unpublished data where possible via email.

A risk-of-bias assessment was performed on RevMan for all included RCTs. The ‘Jadad scale’ checklist was used to assess the quality of RCTs.

**Data analysis**

Meta-analysis was performed on outcomes where data were available from at least two RCTs. ‘Mean change from baseline’ was used for analysis of continuous variables. Data were analysed using either the inverse variance (IV) fixed-effects method or IV random-effects method. If heterogeneity was significant (I²>30%), a random-effects model was used. Effect was measured using either mean difference (MD) or standardised mean difference (SMD). 95% CIs and SDs were used for the analysis. A p value of <0.05 was considered significant. Relative risk (RR) was used in all other analyses. The majority of studies identified for this review did not publish an intention-to-treat analysis; therefore, this review is not based on this principle.

**Quality of the evidence**

The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) Working Group approach was used to assess the quality of evidence produced by this review.

**MAIN RESULTS**

**Search results**

The main search was performed on 8 February 2014. A total of 1440 papers were identified. Figure 1 below lays out the filtering process to leave 18 remaining included studies. Most ‘irrelevant’ studies were related to progesterone therapy as a contraceptive or hormone replacement therapy. A further updated search was performed on 25 August 2015, identifying 34 studies, none of which were relevant.

**Included studies**

Eighteen studies were ultimately included in this review as shown in table 1. Of these, 12 were RCTs and 6 were non-randomised trials/pilot studies. Of the 12 RCTs, 4 compared progesterone therapy with placebo and 8 compared progesterone therapy with other interventions. This totalled 916 patients (HIV/AIDS n=607, ESRF n=95, COPD n=145, geriatric cachexia n=69).

The vast majority of studies looked at MA, with only one using medroxyprogesterone.33 Dose of MA was variable (range: 40 mg–800 mg a day, most common: 800 mg a day). Trial length and timing of analysis was also variable (range: 3 weeks–7 months, most common timing of analysis was 12 weeks).
Characteristics of included studies and risk-of-bias assessment
See online supplementary material.

Data analysis
Progesterone therapy versus placebo
By outcome
Weight change
Figure 2 below includes results from the meta-analysis comparing weight change using the random-effects IV model ($I^2$ 90%—considerate heterogeneity). Adequate data were available from only three RCTs.

Underlying conditions were AIDS, COPD and geriatric cachexia. For all three studies, 800 mg a day MA was used. MD was not statistically significant (MD 1.56, 95% CI $-0.36$ to $3.52$, $p=0.12$).

Data for change in weight were available from 12 studies; 7 RCTs, 5 non-randomised trials, 442 patients. Mean weight change in patients receiving MA was positive in all studies,
ranging from 0.86 kg to 10.2 kg over a follow-up period ranging from 3 weeks to 72 weeks. Mean weight change was only significant in four studies. A clear dose-response gradient with MA was seen in the Von Roenn et al. study (mean weight change 0.86 kg, SD 4.61 with 100 mg a day (n=61); 1.91 kg, SD 4.3 with 400 mg a day (n=53); and 3.54 kg, SD 4.3 with 800 mg a day (n=53)), although no changes were statistically significant.

**Change in LBM**

Data for change in LBM were available from 6 studies; 5 RCTs, 1 non-randomised trial, 342 patients. There were inadequate available RCT data to perform meta-analysis. Four studies used bioelectrical impedance (three reporting fat-free mass (FFM) and one reporting LBM) and two reported anthropological measurements. Five of the six studies reported an increase in mean LBM in patients

### Table 1  Summary of included studies

<table>
<thead>
<tr>
<th>Study name</th>
<th>Intervention total daily dose (mg)</th>
<th>Comparison group(s)</th>
<th>Underlying condition</th>
<th>Participants (n)</th>
<th>Length of trial (weeks)</th>
<th>Jadad score</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Randomised control trials vs placebo</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monfared et al</td>
<td>MA 80</td>
<td>Placebo</td>
<td>ESRF</td>
<td>22</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Von Roenn et al</td>
<td>MA 100 v 400 v 800</td>
<td>Four-arm trial*</td>
<td>AIDS</td>
<td>270</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Weisberg et al</td>
<td>MA 800</td>
<td>Placebo</td>
<td>COPD</td>
<td>145</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Yeh et al</td>
<td>MA 800</td>
<td>Placebo</td>
<td>Geriatric cachexia</td>
<td>69</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td><strong>Randomised control trials vs other interventions</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Batterham and Garcia</td>
<td>MA 400</td>
<td>Three-arm trial:†</td>
<td>HIV</td>
<td>15</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>Mulligan et al</td>
<td>MA 800</td>
<td>MA plus†</td>
<td>HIV</td>
<td>79</td>
<td>12</td>
<td>5</td>
</tr>
<tr>
<td>Mwamburi et al</td>
<td>MA plus dietary advice 800</td>
<td>Oxandrolone</td>
<td>HIV</td>
<td>39</td>
<td>8</td>
<td>3</td>
</tr>
<tr>
<td>Rochon et al</td>
<td>Medroxyprogesterone plus§ 400</td>
<td>Placebo plus§</td>
<td>HIV</td>
<td>12</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Summerbell et al</td>
<td>MA 40 plus¶</td>
<td>Cyproheptadine</td>
<td>HIV</td>
<td>14</td>
<td>12</td>
<td>1</td>
</tr>
<tr>
<td>Timpone et al</td>
<td>MA 750</td>
<td>Four-arm trial:**</td>
<td>HIV</td>
<td>50</td>
<td>12</td>
<td>2</td>
</tr>
<tr>
<td>Wanke et al</td>
<td>MA concentrated solution 575 v 800</td>
<td>Oral solution (800 mg OD)</td>
<td>HIV</td>
<td>63</td>
<td>12</td>
<td>3</td>
</tr>
<tr>
<td>Yeh et al</td>
<td>MA 800</td>
<td>MA plus†</td>
<td>ESRF</td>
<td>9</td>
<td>24</td>
<td>5</td>
</tr>
<tr>
<td><strong>Non-randomised trials</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Golebiowska et al</td>
<td>MA 160</td>
<td></td>
<td>ESRF</td>
<td>32</td>
<td>Up to 6 months (analysis at 8 weeks)</td>
<td></td>
</tr>
<tr>
<td>Graham et al</td>
<td>MA 800</td>
<td></td>
<td>AIDS</td>
<td>14</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>Lien and Ruffenach</td>
<td>MA 40</td>
<td></td>
<td>ESRF</td>
<td>16</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Mwamburi et al</td>
<td>MA plus‡ 800</td>
<td></td>
<td>HIV</td>
<td>29</td>
<td>7 months</td>
<td></td>
</tr>
<tr>
<td>Rammohan et al</td>
<td>MA 400</td>
<td></td>
<td>ESRF</td>
<td>16</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>Von Roenn et al</td>
<td>MA 320 plus§§</td>
<td></td>
<td>ESRF</td>
<td>22</td>
<td>Up to 72 weeks</td>
<td></td>
</tr>
</tbody>
</table>

*(a) 100 mg OD, (b) 400 mg OD, (c) 800 mg OD and (d) placebo.†(a) Dietary counselling (b) nandrolone decanoate (100 mg/fortnight intramuscular injection) (c) megestrol acetate (400 mg/day oral).‡MA plus testosterone versus MA plus placebo.§Nutritional support, amino acid supplementation and protein drinks.¶Increased by 40 mg alternate weeks to maximum dose of 160 mg if no weight gain.**(a) Dronabinol 2.5 mg BD, (b) MA 750 mg OD, (c) MA 750 OD plus dronabinol 2.5 mg BD and (d) MA 250 mg OD plus dronabinol 2.5 mg OD.††Physical training versus placebo plus physical training.‡‡Dietary advice plus oxandrolone.§§Increased by 140 mg if no weight gain after 12 weeks.

COPD, chronic obstructive pulmonary disease; ESRF, end-stage renal failure; MA, megestrol acetate.
receiving MA; however, only one reported significant gain (mean change in FFM 2.76 kg, SD 0.55). A clear dose-response gradient with MA was also seen in the Von Roenn et al. study.

**Appetite**

Raw data were available from 3 studies; 2 RCTs, 1 non-randomised trial, 181 patients. Appetite was measured using a variety of visual scales and questionnaires. There were inadequate raw data to perform meta-analysis. All three studies reported most participants receiving MA reported increased appetite (range 72–100%, mean 79% (143/181)). In the Von Roenn et al. study, a significant dose–response relationship was seen, as well as a significant improvement in appetite compared with placebo (MA 800 mg vs placebo: RR 1.85, 95% CI 1.27 to 2.70, p=0.001, n=83).

**Muscle strength**

No study measured muscle strength (although Weisberg et al. looked at respiratory muscle strength, this was not felt to be synonymous with overall muscle strength).

**Health-related quality of life (HRQOL)**

Results were available from 4 studies; 1 RCT, 3 non-randomised trials, 205 patients using a variety of visual analogue scales and questionnaires. Pooling together all available data, in 61% (126/205) of the patients receiving MA, HRQOL scores increased (range 44–100%). As in other outcomes, there was a clear dose–response gradient seen with MA in the Von Roenn et al. study, with a significant improvement in QOL measures when comparing MA 800 mg a day with placebo (RR 3.0, 95% CI 1.43 to 6.26, p=0.004, n=81).

**Serum albumin**

Meta-analysis was performed with data from two studies: Monfared et al. and Yeh (as shown in figure 2). Underlying conditions were ESRF and geriatric cachexia. MD was not statistically significant comparing MA with placebo (MD 6.35, 95% CI –2.17 to 14.87, p=0.14).

Overall, results were available from 6 studies; 3 RCTs, 3 non-randomised trials, 128 patients. Mean change in serum albumin in patients receiving MA was positive in five of the six studies; however, this was statistically significant in only one study (mean change 8.3 g/L, SD 3.1).

**Analysis by underlying condition**

**HIV/AIDS**

Eleven studies looked at patients with HIV/AIDS; 8 RCTs, 3 non-randomised trials, 607 patients (see table 1). Mean weight gain was significant in three of the six studies; however, unfortunately only one RCT compared directly with placebo, limiting analysis. Mean weight gain ranged from 0.86 to 10.2 kg. One study showed significant gain in LBM, and one other showed a significant improvement in appetite and HRQOL measures.

**End-stage renal failure (ESRF)**

Five studies looked at patients with ESRF; 2 RCTs, 3 non-randomised trials, 95 patients. Yeh et al. found a significant improvement in weight and exercise tolerance. Monfared et al. primarily looked at serum albumin, reporting a significant improvement in malnourished dialysis patient. All three clinical trials showed generally positive results.

**Chronic obstructive pulmonary disease (COPD)**

One study looked at patients with COPD. This was an RCT with 145 participants. Using MA 800 mg a day for 8 weeks, this study reported a significant

---

**Figure 2** Megestrol acetate versus placebo: weight change and change in serum albumin.
improvement in appetite and body weight, as well as ventilation and improved body image (no improvement in respiratory muscle function or exercise tolerance).

Geriatric cachexia

One study looked at patients with geriatric cachexia. This was an RCT with 69 participants. Using MA 800 mg a day for 12 weeks, this study reported a significant improvement in appetite and well-being, but no statistically significant weight gain.

Comparison with other treatments for cachexia

The studies Batterham and Garsia and Mwumburi et al compared progesterone therapy with anabolic steroids. Meta-analysis comparing effect on weight change and LBM showed no observed significant difference (as shown in figures 3 and 4 below). Weight change: MD 2.90, 95% CI −2.83 to 8.64, p = 0.32 (I² 80%, random-effects IV model used). Change in LBM: SMD −0.23, 95% CI −0.85 to 0.38, p = 0.45 (SMD used as different outcome measures used) FFM vs LBM, I² 0%, fixed-effects IV model used. Owing to high variability in data and study design, no other supplementary analysis has been made.

Adverse events

Adverse event data were available from 11 studies. There were no deaths reported to be considered related to progesterone therapy. Von Roenn et al, Von Roenn et al, and Yeh et al reported thromboembolic events in patients receiving MA (one case out of 22 participants, one case out of 270 participants and two cases out of 69 participants, respectively). No proven cases of adrenal insufficiency were reported. Data looking at the incidence of oedema were variably published; however, most studies reported this as a common adverse effect. There were three reported cases of hyperglycaemia/poor diabetic control on starting MA. Other commonly reported side effects include dyspnoea/respiratory complaints, gastrointestinal upset, loss of libido/impotence and generalised weakness.

DISCUSSION

Efficacy

At the time of this review, there were 12 published RCTs and 7 non-randomised trials looking at the use of progesterone therapy for non-cancer cachexia, totalling 916 patients. Included studies were obtained from a literature search looking at multiple surrogate outcome measures for this complex syndrome. The underlying condition in the majority of patients in this analysis was HIV/AIDS. Meta-analyses were limited due to a lack of conformity with regard to methodology and patient groups, and raw data availability. While most studies reported improved outcomes, the quality of the evidence was poor and results variable. This review has therefore concluded that progesterone therapy has not been shown to be effective in the treatment of non-cancer cachexia. It is difficult to ascertain definitively if this is due to the lack of adequately powered randomised trials, or lack of effect. The largest scale RCT (270 participants) did show a dose–response effect, but this was not significant for weight and LBM. Therefore, any effect is likely to be very small and of doubtful clinical significance. The current evidence does however suggest that progesterone therapies may have a positive impact on symptom control, particularly appetite. Most studies with positive results have used MA 400–800 mg a day for 8–12 weeks safely. No trial demonstrated efficacy at a dose <160 mg a day, or treatment for <8 weeks. The duration of effect is unclear. These results are summarised in table 2.

As discussed in the introduction section, cachexia encompasses much more than just low body weight, and many would argue crude ‘weight’ is not the most useful outcome measure in this complex patient group. Only half of the studies included in this review measured LBM, with only one study reporting statistically significant results. No studies measured muscle strength. It should be noted that water retention is a common, recognised side effect of progesterone therapy; thus, the nutritional effect of any observed weight gain is unclear. The best way of measuring muscle mass has been debated. The most effective techniques include cross-sectional imaging and dual-energy X-ray absorptiometry (DEXA) scanning; however, these are expensive and time-consuming (and rarely done in clinical practice). Methods such as bioelectrical impedance and anthropological measurements are simple and cheap; however, accuracy in patients at the extremes of age and body habitus has been questioned. Recent guidelines for the

<table>
<thead>
<tr>
<th>Study or Subgroup</th>
<th>Megestrol acetate Mean</th>
<th>SD</th>
<th>Total</th>
<th>Anabolic steroid Mean</th>
<th>SD</th>
<th>Total</th>
<th>Weight</th>
<th>Mean Difference IV, Random, 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Batterham 2001 (1)</td>
<td>10.2</td>
<td>4.51</td>
<td>4</td>
<td>4.01</td>
<td>1.68</td>
<td>8</td>
<td>44.2%</td>
<td>6.19 [1.62, 10.76]</td>
</tr>
<tr>
<td>Mwumburi 2004 (2)</td>
<td>2.8</td>
<td>4.3</td>
<td>4</td>
<td>2.5</td>
<td>2.4</td>
<td>15</td>
<td>55.8%</td>
<td>0.30 [-2.03, 2.63]</td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>22</td>
<td></td>
<td>23</td>
<td>23</td>
<td></td>
<td></td>
<td>100.0%</td>
<td>2.90 [-2.83, 8.64]</td>
</tr>
<tr>
<td>Heterogeneity: Tau²:</td>
<td>13.92</td>
<td></td>
<td></td>
<td>5.07</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>F = 1 (P = 0.02); I²:</td>
<td></td>
<td></td>
<td>80%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Test for overall effect: Z = 0.99 (P = 0.32)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 3 Megestrol acetate versus anabolic steroid: weight change.
identification of cachexia have differed slightly in their recommendations for muscle mass measurements. We suggest collection of muscle mass data should be included in any future studies; however, careful consideration of chosen measurement techniques should be made.

Markers of improved symptom control are of great significance in cachexia where aetiology is often multifactorial and irreversible. One study dominated results in this area, showing a clear dose–response gradient for appetite and HRQOL for patients with HIV. Weisberg et al demonstrated improved appetite and improved body image in patients with COPD, and Yeh et al showed improved appetite and well-being in patients with geriatric cachexia. These results are promising and may justify the use of progesterone therapies in palliative patients where QOL rather than nutritional status is the priority. It would be useful for further studies to focus more clearly on the impact on symptom control as current evidence is of low quality.

Serum albumin is an interesting outcome measure. Biochemical markers of nutritional status are influenced by many outside factors and may not give an accurate picture of overall nutritional health. Meta-analysis looking at the impact of MA on serum albumin showed insignificant results. This outcome has not been measured in other reviews, so no comparison can be made to current literature. It should be noted that most data for this outcome were gained from patients with ESRF, thus potential confounding factors are significant when applying these results to a wider cohort (eg, impact of dialysis).

Heterogeneity was extremely high in this review, with a huge variation in dose of progesterone, length of treatment and duration of follow-up—all of which could have influenced results. Besides this, the diversity of patient characteristics was great, with a spectrum of underlying conditions, comorbidities and prognoses. Studies looking at HIV/AIDS have provided the majority of data for this review, making up 66% of the total patients included. It is difficult to say if this could skew results when applied to all patients; however, looking at magnitude of weight gain, this was varied but of a similar trend across all disease

![Table 2](image-url)

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Meta-analysis</th>
<th>Other analysis</th>
<th>Conclusion</th>
<th>Quality of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weight change</td>
<td>No significant change in weight compared with placebo or anabolic steroids.</td>
<td>Compared with placebo, mean weight gain was positive in all included studies (significant in four).</td>
<td>Progesterone therapy is likely to cause a small increase in weight.</td>
<td>GRADE scale: moderate</td>
</tr>
<tr>
<td>LBM</td>
<td>Insufficient data to compare with placebo. Comparison with anabolic steroids: no significant difference.</td>
<td>Five of the six studies where data were available reported an increase in mean LBM (significant in one).</td>
<td>Progesterone therapy may cause a small increase in LBM, but this is unlikely to be of any significant magnitude.</td>
<td>GRADE scale: low</td>
</tr>
<tr>
<td>Appetite</td>
<td>Insufficient data.</td>
<td>All three studies where data were available reported significant improvement in appetite. Two others also reported significant results.</td>
<td>Progesterone therapy is likely to cause an improvement in appetite.</td>
<td>GRADE scale: low</td>
</tr>
<tr>
<td>Muscle strength</td>
<td>No study measured this outcome.</td>
<td>Nil</td>
<td>There is no evidence to show progesterone therapy has any influence over muscle strength.</td>
<td>GRADE scale: low</td>
</tr>
<tr>
<td>HRQOL</td>
<td>Insufficient data.</td>
<td>In all four studies, mean change in HRQOL measures was positive (but unclear is significantly so).</td>
<td>Progesterone therapy may cause some improvement in HRQOL measures.</td>
<td>GRADE scale: low</td>
</tr>
<tr>
<td>Serum albumin</td>
<td>No significant change in serum albumin compared with placebo.</td>
<td>In five of the six studies where data were available, mean change in serum albumin was positive (only significant in one study).</td>
<td>Progesterone therapy may cause a small increase in serum albumin.</td>
<td>GRADE scale: low</td>
</tr>
</tbody>
</table>

GRADE, Grading of Recommendations, Assessment, Development and Evaluations; HRQOL, health-related quality of life; LBM, lean body mass.
groups (mean weight gain ranged from 0.86 to 10.2 kg in studies looking at HIV/AIDS, 1.2–9 kg in ESRF, 3.2 in COPD and 1.05 in geriatric cachexia). It is difficult to compare other outcomes owing to a lack of raw data.

Safety profile
Progesterone therapy appeared to be relatively safe with a limited range of serious adverse effects. This review included 916 patients, with no deaths reported to be linked to progesterone therapy. The rate of thromboembolic events from pooled data was approximately 1% (4/361). The 2005 Cochrane review (looking at all patients with cachexia) performed a safety analysis including over 3000 patients. This concluded that mortality rates were increased in patients receiving MA, and risk appeared to be greater with higher doses (RR 1.43, 95% CI 1.05 to 1.96). A large retrospective case-controlled study of 709 nursing home patients with weight loss in America also reported increased mortality in patients receiving MA. The reason for this remains unclear; however, the Cochrane review also reported a slightly higher (but insignificant) increase in rates of thromboembolic phenomenon in patients receiving MA.

The most common serious adverse events appear to be secondary to progesterone’s glucocorticoid effect. While this review found no proven case of adrenal insufficiency, there is good evidence in the literature to suggest this can be an adverse effect. A report by the US Food and Drug Administration in 1997 acknowledged these adverse effects. Therefore, clinicians should be aware of these when initiating/withdrawing therapy.

Limitations of this review
The methodology of this review was limited by available resources. The majority of data extraction and analysis was performed by JKT only. Ideally, this process should have been performed by two or more independent investigators. A significant ‘recurring theme’ during this review was missing data. Analysis was limited in the main part owing to the lack of published raw data, or unclear statistical methods. Only four authors responded to data requests. ‘Dealing with missing data’ is a common problem, and it’s impact on results is difficult to predict.

No trial included patients based on a diagnosis of ‘cachexia’ using diagnostic scores as described in the introduction section. This was anticipated as these scores do not seem to be widely used. Unfortunately, it was not possible to perform any analysis of efficacy based on severity of symptoms owing to poor data quality. Broad ‘inclusion criteria’ has meant potentially patients without true cachexia have been included, particularly those with pure weight loss without cachexia, or sarcopenia. It was difficult to devise a way around this problem without excluding a significant number of studies; therefore, conclusions should be made with this caveat.

AUTHOR’S CONCLUSIONS
There is a lack of evidence to demonstrate progesterone therapy causes nutritionally significant weight gain in patients with non-cancer cachexia; thus, its routine clinical use cannot be recommended. Its impact on symptoms such as appetite and HRQOL however is generally positive (but evidence is of low quality). This review did not find any evidence of increased mortality in patients receiving progesterone therapy; however, larger reviews including patients with cancer have reported increased mortality rates, possibly due to increased risk of venous thromboembolism. Other serious adverse events include adrenal insufficiency, and clinicians should be aware of this if initiating and withdrawing therapy. Fluid retention is a commonly reported side effect and may account for some observed weight gain. These findings are broadly similar to those made in the Cochrane Review of Megestrol acetate for anorexia-cachexia syndrome and the EPCRC Cachexia Guidelines 2011. Despite repeated calls for greater research in this field, there remains a lack of good-quality trial data, particularly in patients without cancer.

Implications for practice
This review does not currently recommend the routine use of progesterone therapy for cachexia in patients without cancer. It may be justified with the aim of improving symptom control in a palliative context, however only on a case-by-case basis with appreciation of its adverse effect profile.

Implications for research
The quality of evidence remains poor, and more RCTs of progesterone therapy for patients with conditions such as HIV/AIDS, ESRF, COPD and geriatric cachexia are required. An increased focus on outcome measures such as LBM, muscle strength/functional status and HRQOL would be helpful to clarify the efficacy of progesterone therapies with appetite stimulation.

Acknowledgements
The authors would like to acknowledge the contributions of Marshall Dozier (Senior Liaison Librarian for the College of Medicine and Veterinary Medicine) for advice regarding the literature search.

Competing interests
None declared.

Provenance and peer review
Not commissioned; externally peer reviewed.

REFERENCES
2 Monfared A, Heidarzadeh A, Ghaffari M, *et al*. Effect of megestrol acetate on serum albumin level in malnourished


7 Borst SE. The role of TNF-alpha in insulin resistance. Endocrine 2004;23:177–82.


